PARPi also improves anti-tumor immunity independently of BRCA background, as shown in vivo in C57BL/6 mice with MB49 xenograft tumors [142], but olaparib in conjunction with STING agonists impedes the growth of BRCA1-deficient breast cancer in wild-type mice but shows no impact in mice with STING-KO variants [143]. This evidence concerns the gene BRCA1 and neoplasm.